Personal Care Preservatives
The research report includes specific segments by region (country), by manufacturers, by Type and ... Read More
Global Overactive Bladder Diagnosis and Treatment Market Research Report 2024
1 Overactive Bladder Diagnosis and Treatment Market Overview
1.1 Product Overview and Scope of Overactive Bladder Diagnosis and Treatment
1.2 Overactive Bladder Diagnosis and Treatment Segment by Type
1.2.1 Global Overactive Bladder Diagnosis and Treatment Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Anticholinergics
1.2.3 Mirabegron
1.2.4 BOTOX
1.2.5 Neuromodulation
1.2.6 Others
1.3 Overactive Bladder Diagnosis and Treatment Segment by Application
1.3.1 Global Overactive Bladder Diagnosis and Treatment Sales Comparison by Application: (2022-2028)
1.3.2 Idiopathic Overactive Bladder
1.3.3 Neurogenic Overactive Bladder
1.4 Global Overactive Bladder Diagnosis and Treatment Market Size Estimates and Forecasts
1.4.1 Global Overactive Bladder Diagnosis and Treatment Revenue 2017-2028
1.4.2 Global Overactive Bladder Diagnosis and Treatment Sales 2017-2028
1.4.3 Overactive Bladder Diagnosis and Treatment Market Size by Region: 2017 Versus 2021 Versus 2028
2 Overactive Bladder Diagnosis and Treatment Market Competition by Manufacturers
2.1 Global Overactive Bladder Diagnosis and Treatment Sales Market Share by Manufacturers (2017-2022)
2.2 Global Overactive Bladder Diagnosis and Treatment Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Overactive Bladder Diagnosis and Treatment Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Overactive Bladder Diagnosis and Treatment Manufacturing Sites, Area Served, Product Type
2.5 Overactive Bladder Diagnosis and Treatment Market Competitive Situation and Trends
2.5.1 Overactive Bladder Diagnosis and Treatment Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Overactive Bladder Diagnosis and Treatment Players Market Share by Revenue
2.5.3 Global Overactive Bladder Diagnosis and Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Overactive Bladder Diagnosis and Treatment Retrospective Market Scenario by Region
3.1 Global Overactive Bladder Diagnosis and Treatment Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Overactive Bladder Diagnosis and Treatment Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Overactive Bladder Diagnosis and Treatment Market Facts & Figures by Country
3.3.1 North America Overactive Bladder Diagnosis and Treatment Sales by Country
3.3.2 North America Overactive Bladder Diagnosis and Treatment Revenue by Country
3.3.3 United States
3.3.4 Canada
3.4 Europe Overactive Bladder Diagnosis and Treatment Market Facts & Figures by Country
3.4.1 Europe Overactive Bladder Diagnosis and Treatment Sales by Country
3.4.2 Europe Overactive Bladder Diagnosis and Treatment Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Overactive Bladder Diagnosis and Treatment Market Facts & Figures by Region
3.5.1 Asia Pacific Overactive Bladder Diagnosis and Treatment Sales by Region
3.5.2 Asia Pacific Overactive Bladder Diagnosis and Treatment Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Overactive Bladder Diagnosis and Treatment Market Facts & Figures by Country
3.6.1 Latin America Overactive Bladder Diagnosis and Treatment Sales by Country
3.6.2 Latin America Overactive Bladder Diagnosis and Treatment Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.6.6 Colombia
3.7 Middle East and Africa Overactive Bladder Diagnosis and Treatment Market Facts & Figures by Country
3.7.1 Middle East and Africa Overactive Bladder Diagnosis and Treatment Sales by Country
3.7.2 Middle East and Africa Overactive Bladder Diagnosis and Treatment Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Overactive Bladder Diagnosis and Treatment Historic Market Analysis by Type
4.1 Global Overactive Bladder Diagnosis and Treatment Sales Market Share by Type (2017-2022)
4.2 Global Overactive Bladder Diagnosis and Treatment Revenue Market Share by Type (2017-2022)
4.3 Global Overactive Bladder Diagnosis and Treatment Price by Type (2017-2022)
5 Global Overactive Bladder Diagnosis and Treatment Historic Market Analysis by Application
5.1 Global Overactive Bladder Diagnosis and Treatment Sales Market Share by Application (2017-2022)
5.2 Global Overactive Bladder Diagnosis and Treatment Revenue Market Share by Application (2017-2022)
5.3 Global Overactive Bladder Diagnosis and Treatment Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Astellas Pharma Inc
6.1.1 Astellas Pharma Inc Corporation Information
6.1.2 Astellas Pharma Inc Description and Business Overview
6.1.3 Astellas Pharma Inc Overactive Bladder Diagnosis and Treatment Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Astellas Pharma Inc Overactive Bladder Diagnosis and Treatment Product Portfolio
6.1.5 Astellas Pharma Inc Recent Developments/Updates
6.2 Teva Pharmaceutical Industries
6.2.1 Teva Pharmaceutical Industries Corporation Information
6.2.2 Teva Pharmaceutical Industries Description and Business Overview
6.2.3 Teva Pharmaceutical Industries Overactive Bladder Diagnosis and Treatment Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Teva Pharmaceutical Industries Overactive Bladder Diagnosis and Treatment Product Portfolio
6.2.5 Teva Pharmaceutical Industries Recent Developments/Updates
6.3 Pfizer Inc
6.3.1 Pfizer Inc Corporation Information
6.3.2 Pfizer Inc Description and Business Overview
6.3.3 Pfizer Inc Overactive Bladder Diagnosis and Treatment Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Pfizer Inc Overactive Bladder Diagnosis and Treatment Product Portfolio
6.3.5 Pfizer Inc Recent Developments/Updates
6.4 Abbvie Inc
6.4.1 Abbvie Inc Corporation Information
6.4.2 Abbvie Inc Description and Business Overview
6.4.3 Abbvie Inc Overactive Bladder Diagnosis and Treatment Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Abbvie Inc Overactive Bladder Diagnosis and Treatment Product Portfolio
6.4.5 Abbvie Inc Recent Developments/Updates
6.5 Viatris Inc
6.5.1 Viatris Inc Corporation Information
6.5.2 Viatris Inc Description and Business Overview
6.5.3 Viatris Inc Overactive Bladder Diagnosis and Treatment Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Viatris Inc Overactive Bladder Diagnosis and Treatment Product Portfolio
6.5.5 Viatris Inc Recent Developments/Updates
6.6 Hisamitsu Pharmaceutical
6.6.1 Hisamitsu Pharmaceutical Corporation Information
6.6.2 Hisamitsu Pharmaceutical Description and Business Overview
6.6.3 Hisamitsu Pharmaceutical Overactive Bladder Diagnosis and Treatment Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Hisamitsu Pharmaceutical Overactive Bladder Diagnosis and Treatment Product Portfolio
6.6.5 Hisamitsu Pharmaceutical Recent Developments/Updates
6.7 Johnson & Johnson Services
6.6.1 Johnson & Johnson Services Corporation Information
6.6.2 Johnson & Johnson Services Description and Business Overview
6.6.3 Johnson & Johnson Services Overactive Bladder Diagnosis and Treatment Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Johnson & Johnson Services Overactive Bladder Diagnosis and Treatment Product Portfolio
6.7.5 Johnson & Johnson Services Recent Developments/Updates
6.8 Endo Pharmaceuticals
6.8.1 Endo Pharmaceuticals Corporation Information
6.8.2 Endo Pharmaceuticals Description and Business Overview
6.8.3 Endo Pharmaceuticals Overactive Bladder Diagnosis and Treatment Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Endo Pharmaceuticals Overactive Bladder Diagnosis and Treatment Product Portfolio
6.8.5 Endo Pharmaceuticals Recent Developments/Updates
6.9 Lupin
6.9.1 Lupin Corporation Information
6.9.2 Lupin Description and Business Overview
6.9.3 Lupin Overactive Bladder Diagnosis and Treatment Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Lupin Overactive Bladder Diagnosis and Treatment Product Portfolio
6.9.5 Lupin Recent Developments/Updates
6.10 KYORIN Pharmaceutical
6.10.1 KYORIN Pharmaceutical Corporation Information
6.10.2 KYORIN Pharmaceutical Description and Business Overview
6.10.3 KYORIN Pharmaceutical Overactive Bladder Diagnosis and Treatment Sales, Revenue and Gross Margin (2017-2022)
6.10.4 KYORIN Pharmaceutical Overactive Bladder Diagnosis and Treatment Product Portfolio
6.10.5 KYORIN Pharmaceutical Recent Developments/Updates
6.11 Amneal Pharmaceuticals
6.11.1 Amneal Pharmaceuticals Corporation Information
6.11.2 Amneal Pharmaceuticals Overactive Bladder Diagnosis and Treatment Description and Business Overview
6.11.3 Amneal Pharmaceuticals Overactive Bladder Diagnosis and Treatment Sales, Revenue and Gross Margin (2017-2022)
6.11.4 Amneal Pharmaceuticals Overactive Bladder Diagnosis and Treatment Product Portfolio
6.11.5 Amneal Pharmaceuticals Recent Developments/Updates
6.12 Sun Pharmaceutical Industries
6.12.1 Sun Pharmaceutical Industries Corporation Information
6.12.2 Sun Pharmaceutical Industries Overactive Bladder Diagnosis and Treatment Description and Business Overview
6.12.3 Sun Pharmaceutical Industries Overactive Bladder Diagnosis and Treatment Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Sun Pharmaceutical Industries Overactive Bladder Diagnosis and Treatment Product Portfolio
6.12.5 Sun Pharmaceutical Industries Recent Developments/Updates
6.13 Glenmark
6.13.1 Glenmark Corporation Information
6.13.2 Glenmark Overactive Bladder Diagnosis and Treatment Description and Business Overview
6.13.3 Glenmark Overactive Bladder Diagnosis and Treatment Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Glenmark Overactive Bladder Diagnosis and Treatment Product Portfolio
6.13.5 Glenmark Recent Developments/Updates
6.14 Macleods Pharmaceuticals
6.14.1 Macleods Pharmaceuticals Corporation Information
6.14.2 Macleods Pharmaceuticals Overactive Bladder Diagnosis and Treatment Description and Business Overview
6.14.3 Macleods Pharmaceuticals Overactive Bladder Diagnosis and Treatment Sales, Revenue and Gross Margin (2017-2022)
6.14.4 Macleods Pharmaceuticals Overactive Bladder Diagnosis and Treatment Product Portfolio
6.14.5 Macleods Pharmaceuticals Recent Developments/Updates
6.15 Medtronic
6.15.1 Medtronic Corporation Information
6.15.2 Medtronic Overactive Bladder Diagnosis and Treatment Description and Business Overview
6.15.3 Medtronic Overactive Bladder Diagnosis and Treatment Sales, Revenue and Gross Margin (2017-2022)
6.15.4 Medtronic Overactive Bladder Diagnosis and Treatment Product Portfolio
6.15.5 Medtronic Recent Developments/Updates
6.16 Ajanta Pharma
6.16.1 Ajanta Pharma Corporation Information
6.16.2 Ajanta Pharma Overactive Bladder Diagnosis and Treatment Description and Business Overview
6.16.3 Ajanta Pharma Overactive Bladder Diagnosis and Treatment Sales, Revenue and Gross Margin (2017-2022)
6.16.4 Ajanta Pharma Overactive Bladder Diagnosis and Treatment Product Portfolio
6.16.5 Ajanta Pharma Recent Developments/Updates
6.17 Granules India
6.17.1 Granules India Corporation Information
6.17.2 Granules India Overactive Bladder Diagnosis and Treatment Description and Business Overview
6.17.3 Granules India Overactive Bladder Diagnosis and Treatment Sales, Revenue and Gross Margin (2017-2022)
6.17.4 Granules India Overactive Bladder Diagnosis and Treatment Product Portfolio
6.17.5 Granules India Recent Developments/Updates
6.18 Urovant Sciences
6.18.1 Urovant Sciences Corporation Information
6.18.2 Urovant Sciences Overactive Bladder Diagnosis and Treatment Description and Business Overview
6.18.3 Urovant Sciences Overactive Bladder Diagnosis and Treatment Sales, Revenue and Gross Margin (2017-2022)
6.18.4 Urovant Sciences Overactive Bladder Diagnosis and Treatment Product Portfolio
6.18.5 Urovant Sciences Recent Developments/Updates
6.19 Apotex Inc.
6.19.1 Apotex Inc. Corporation Information
6.19.2 Apotex Inc. Overactive Bladder Diagnosis and Treatment Description and Business Overview
6.19.3 Apotex Inc. Overactive Bladder Diagnosis and Treatment Sales, Revenue and Gross Margin (2017-2022)
6.19.4 Apotex Inc. Overactive Bladder Diagnosis and Treatment Product Portfolio
6.19.5 Apotex Inc. Recent Developments/Updates
7 Overactive Bladder Diagnosis and Treatment Manufacturing Cost Analysis
7.1 Overactive Bladder Diagnosis and Treatment Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Overactive Bladder Diagnosis and Treatment
7.4 Overactive Bladder Diagnosis and Treatment Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Overactive Bladder Diagnosis and Treatment Distributors List
8.3 Overactive Bladder Diagnosis and Treatment Customers
9 Overactive Bladder Diagnosis and Treatment Market Dynamics
9.1 Overactive Bladder Diagnosis and Treatment Industry Trends
9.2 Overactive Bladder Diagnosis and Treatment Market Drivers
9.3 Overactive Bladder Diagnosis and Treatment Market Challenges
9.4 Overactive Bladder Diagnosis and Treatment Market Restraints
10 Global Market Forecast
10.1 Overactive Bladder Diagnosis and Treatment Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Overactive Bladder Diagnosis and Treatment by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Overactive Bladder Diagnosis and Treatment by Type (2023-2028)
10.2 Overactive Bladder Diagnosis and Treatment Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Overactive Bladder Diagnosis and Treatment by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Overactive Bladder Diagnosis and Treatment by Application (2023-2028)
10.3 Overactive Bladder Diagnosis and Treatment Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Overactive Bladder Diagnosis and Treatment by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Overactive Bladder Diagnosis and Treatment by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Overactive Bladder Diagnosis and Treatment Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
Table 2. Global Overactive Bladder Diagnosis and Treatment Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million)
Table 3. Global Overactive Bladder Diagnosis and Treatment Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Overactive Bladder Diagnosis and Treatment Market Competitive Situation by Manufacturers in 2021
Table 5. Global Overactive Bladder Diagnosis and Treatment Sales (K Units) of Key Manufacturers (2017-2022)
Table 6. Global Overactive Bladder Diagnosis and Treatment Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Overactive Bladder Diagnosis and Treatment Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Overactive Bladder Diagnosis and Treatment Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Overactive Bladder Diagnosis and Treatment Average Price (US$/Unit) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Overactive Bladder Diagnosis and Treatment Manufacturing Sites and Area Served
Table 11. Manufacturers Overactive Bladder Diagnosis and Treatment Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Overactive Bladder Diagnosis and Treatment by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Overactive Bladder Diagnosis and Treatment as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Overactive Bladder Diagnosis and Treatment Sales by Region (2017-2022) & (K Units)
Table 16. Global Overactive Bladder Diagnosis and Treatment Sales Market Share by Region (2017-2022)
Table 17. Global Overactive Bladder Diagnosis and Treatment Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Overactive Bladder Diagnosis and Treatment Revenue Market Share by Region (2017-2022)
Table 19. North America Overactive Bladder Diagnosis and Treatment Sales by Country (2017-2022) & (K Units)
Table 20. North America Overactive Bladder Diagnosis and Treatment Sales Market Share by Country (2017-2022)
Table 21. North America Overactive Bladder Diagnosis and Treatment Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Overactive Bladder Diagnosis and Treatment Revenue Market Share by Country (2017-2022)
Table 23. Europe Overactive Bladder Diagnosis and Treatment Sales by Country (2017-2022) & (K Units)
Table 24. Europe Overactive Bladder Diagnosis and Treatment Sales Market Share by Country (2017-2022)
Table 25. Europe Overactive Bladder Diagnosis and Treatment Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Overactive Bladder Diagnosis and Treatment Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Overactive Bladder Diagnosis and Treatment Sales by Region (2017-2022) & (K Units)
Table 28. Asia Pacific Overactive Bladder Diagnosis and Treatment Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Overactive Bladder Diagnosis and Treatment Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Overactive Bladder Diagnosis and Treatment Revenue Market Share by Region (2017-2022)
Table 31. Latin America Overactive Bladder Diagnosis and Treatment Sales by Country (2017-2022) & (K Units)
Table 32. Latin America Overactive Bladder Diagnosis and Treatment Sales Market Share by Country (2017-2022)
Table 33. Latin America Overactive Bladder Diagnosis and Treatment Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Overactive Bladder Diagnosis and Treatment Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Overactive Bladder Diagnosis and Treatment Sales by Country (2017-2022) & (K Units)
Table 36. Middle East and Africa Overactive Bladder Diagnosis and Treatment Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Overactive Bladder Diagnosis and Treatment Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Overactive Bladder Diagnosis and Treatment Revenue Market Share by Country (2017-2022)
Table 39. Global Overactive Bladder Diagnosis and Treatment Sales by Type (2017-2022) & (K Units)
Table 40. Global Overactive Bladder Diagnosis and Treatment Sales Market Share by Type (2017-2022)
Table 41. Global Overactive Bladder Diagnosis and Treatment Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Overactive Bladder Diagnosis and Treatment Revenue Share by Type (2017-2022)
Table 43. Global Overactive Bladder Diagnosis and Treatment Price by Type (2017-2022) & (US$/Unit)
Table 44. Global Overactive Bladder Diagnosis and Treatment Sales (K Units) by Application (2017-2022)
Table 45. Global Overactive Bladder Diagnosis and Treatment Sales Market Share by Application (2017-2022)
Table 46. Global Overactive Bladder Diagnosis and Treatment Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Overactive Bladder Diagnosis and Treatment Revenue Share by Application (2017-2022)
Table 48. Global Overactive Bladder Diagnosis and Treatment Price by Application (2017-2022) & (US$/Unit)
Table 49. Astellas Pharma Inc Corporation Information
Table 50. Astellas Pharma Inc Description and Business Overview
Table 51. Astellas Pharma Inc Overactive Bladder Diagnosis and Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 52. Astellas Pharma Inc Overactive Bladder Diagnosis and Treatment Product
Table 53. Astellas Pharma Inc Recent Developments/Updates
Table 54. Teva Pharmaceutical Industries Corporation Information
Table 55. Teva Pharmaceutical Industries Description and Business Overview
Table 56. Teva Pharmaceutical Industries Overactive Bladder Diagnosis and Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 57. Teva Pharmaceutical Industries Overactive Bladder Diagnosis and Treatment Product
Table 58. Teva Pharmaceutical Industries Recent Developments/Updates
Table 59. Pfizer Inc Corporation Information
Table 60. Pfizer Inc Description and Business Overview
Table 61. Pfizer Inc Overactive Bladder Diagnosis and Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 62. Pfizer Inc Overactive Bladder Diagnosis and Treatment Product
Table 63. Pfizer Inc Recent Developments/Updates
Table 64. Abbvie Inc Corporation Information
Table 65. Abbvie Inc Description and Business Overview
Table 66. Abbvie Inc Overactive Bladder Diagnosis and Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 67. Abbvie Inc Overactive Bladder Diagnosis and Treatment Product
Table 68. Abbvie Inc Recent Developments/Updates
Table 69. Viatris Inc Corporation Information
Table 70. Viatris Inc Description and Business Overview
Table 71. Viatris Inc Overactive Bladder Diagnosis and Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 72. Viatris Inc Overactive Bladder Diagnosis and Treatment Product
Table 73. Viatris Inc Recent Developments/Updates
Table 74. Hisamitsu Pharmaceutical Corporation Information
Table 75. Hisamitsu Pharmaceutical Description and Business Overview
Table 76. Hisamitsu Pharmaceutical Overactive Bladder Diagnosis and Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 77. Hisamitsu Pharmaceutical Overactive Bladder Diagnosis and Treatment Product
Table 78. Hisamitsu Pharmaceutical Recent Developments/Updates
Table 79. Johnson & Johnson Services Corporation Information
Table 80. Johnson & Johnson Services Description and Business Overview
Table 81. Johnson & Johnson Services Overactive Bladder Diagnosis and Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 82. Johnson & Johnson Services Overactive Bladder Diagnosis and Treatment Product
Table 83. Johnson & Johnson Services Recent Developments/Updates
Table 84. Endo Pharmaceuticals Corporation Information
Table 85. Endo Pharmaceuticals Description and Business Overview
Table 86. Endo Pharmaceuticals Overactive Bladder Diagnosis and Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 87. Endo Pharmaceuticals Overactive Bladder Diagnosis and Treatment Product
Table 88. Endo Pharmaceuticals Recent Developments/Updates
Table 89. Lupin Corporation Information
Table 90. Lupin Description and Business Overview
Table 91. Lupin Overactive Bladder Diagnosis and Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 92. Lupin Overactive Bladder Diagnosis and Treatment Product
Table 93. Lupin Recent Developments/Updates
Table 94. KYORIN Pharmaceutical Corporation Information
Table 95. KYORIN Pharmaceutical Description and Business Overview
Table 96. KYORIN Pharmaceutical Overactive Bladder Diagnosis and Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 97. KYORIN Pharmaceutical Overactive Bladder Diagnosis and Treatment Product
Table 98. KYORIN Pharmaceutical Recent Developments/Updates
Table 99. Amneal Pharmaceuticals Corporation Information
Table 100. Amneal Pharmaceuticals Description and Business Overview
Table 101. Amneal Pharmaceuticals Overactive Bladder Diagnosis and Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 102. Amneal Pharmaceuticals Overactive Bladder Diagnosis and Treatment Product
Table 103. Amneal Pharmaceuticals Recent Developments/Updates
Table 104. Sun Pharmaceutical Industries Corporation Information
Table 105. Sun Pharmaceutical Industries Description and Business Overview
Table 106. Sun Pharmaceutical Industries Overactive Bladder Diagnosis and Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 107. Sun Pharmaceutical Industries Overactive Bladder Diagnosis and Treatment Product
Table 108. Sun Pharmaceutical Industries Recent Developments/Updates
Table 109. Glenmark Corporation Information
Table 110. Glenmark Description and Business Overview
Table 111. Glenmark Overactive Bladder Diagnosis and Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 112. Glenmark Overactive Bladder Diagnosis and Treatment Product
Table 113. Glenmark Recent Developments/Updates
Table 114. Macleods Pharmaceuticals Corporation Information
Table 115. Macleods Pharmaceuticals Description and Business Overview
Table 116. Macleods Pharmaceuticals Overactive Bladder Diagnosis and Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 117. Macleods Pharmaceuticals Overactive Bladder Diagnosis and Treatment Product
Table 118. Macleods Pharmaceuticals Recent Developments/Updates
Table 119. Medtronic Corporation Information
Table 120. Medtronic Description and Business Overview
Table 121. Medtronic Overactive Bladder Diagnosis and Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 122. Medtronic Overactive Bladder Diagnosis and Treatment Product
Table 123. Medtronic Recent Developments/Updates
Table 124. Ajanta Pharma Corporation Information
Table 125. Ajanta Pharma Description and Business Overview
Table 126. Ajanta Pharma Overactive Bladder Diagnosis and Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 127. Ajanta Pharma Overactive Bladder Diagnosis and Treatment Product
Table 128. Ajanta Pharma Recent Developments/Updates
Table 129. Granules India Corporation Information
Table 130. Granules India Description and Business Overview
Table 131. Granules India Overactive Bladder Diagnosis and Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 132. Granules India Overactive Bladder Diagnosis and Treatment Product
Table 133. Granules India Recent Developments/Updates
Table 134. Urovant Sciences Corporation Information
Table 135. Urovant Sciences Description and Business Overview
Table 136. Urovant Sciences Overactive Bladder Diagnosis and Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 137. Urovant Sciences Overactive Bladder Diagnosis and Treatment Product
Table 138. Urovant Sciences Recent Developments/Updates
Table 139. Apotex Inc. Corporation Information
Table 140. Apotex Inc. Description and Business Overview
Table 141. Apotex Inc. Overactive Bladder Diagnosis and Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 142. Apotex Inc. Overactive Bladder Diagnosis and Treatment Product
Table 143. Apotex Inc. Recent Developments/Updates
Table 144. Production Base and Market Concentration Rate of Raw Material
Table 145. Key Suppliers of Raw Materials
Table 146. Overactive Bladder Diagnosis and Treatment Distributors List
Table 147. Overactive Bladder Diagnosis and Treatment Customers List
Table 148. Overactive Bladder Diagnosis and Treatment Market Trends
Table 149. Overactive Bladder Diagnosis and Treatment Market Drivers
Table 150. Overactive Bladder Diagnosis and Treatment Market Challenges
Table 151. Overactive Bladder Diagnosis and Treatment Market Restraints
Table 152. Global Overactive Bladder Diagnosis and Treatment Sales Forecast by Type (2023-2028) & (K Units)
Table 153. Global Overactive Bladder Diagnosis and Treatment Sales Market Share Forecast by Type (2023-2028)
Table 154. Global Overactive Bladder Diagnosis and Treatment Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 155. Global Overactive Bladder Diagnosis and Treatment Revenue Market Share Forecast by Type (2023-2028)
Table 156. Global Overactive Bladder Diagnosis and Treatment Sales Forecast by Application (2023-2028) & (K Units)
Table 157. Global Overactive Bladder Diagnosis and Treatment Sales Market Share Forecast by Application (2023-2028)
Table 158. Global Overactive Bladder Diagnosis and Treatment Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 159. Global Overactive Bladder Diagnosis and Treatment Revenue Market Share Forecast by Application (2023-2028)
Table 160. Global Overactive Bladder Diagnosis and Treatment Sales Forecast by Region (2023-2028) & (K Units)
Table 161. Global Overactive Bladder Diagnosis and Treatment Sales Market Share Forecast by Region (2023-2028)
Table 162. Global Overactive Bladder Diagnosis and Treatment Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 163. Global Overactive Bladder Diagnosis and Treatment Revenue Market Share Forecast by Region (2023-2028)
Table 164. Research Programs/Design for This Report
Table 165. Key Data Information from Secondary Sources
Table 166. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Overactive Bladder Diagnosis and Treatment
Figure 2. Global Overactive Bladder Diagnosis and Treatment Market Share by Type in 2021 & 2028
Figure 3. Anticholinergics Product Picture
Figure 4. Mirabegron Product Picture
Figure 5. BOTOX Product Picture
Figure 6. Neuromodulation Product Picture
Figure 7. Others Product Picture
Figure 8. Global Overactive Bladder Diagnosis and Treatment Market Share by Application in 2021 & 2028
Figure 9. Idiopathic Overactive Bladder
Figure 10. Neurogenic Overactive Bladder
Figure 11. Global Overactive Bladder Diagnosis and Treatment Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global Overactive Bladder Diagnosis and Treatment Market Size (2017-2028) & (US$ Million)
Figure 13. Global Overactive Bladder Diagnosis and Treatment Sales (2017-2028) & (K Units)
Figure 14. Overactive Bladder Diagnosis and Treatment Sales Share by Manufacturers in 2021
Figure 15. Global Overactive Bladder Diagnosis and Treatment Revenue Share by Manufacturers in 2021
Figure 16. The Global 5 and 10 Largest Overactive Bladder Diagnosis and Treatment Players: Market Share by Revenue in 2021
Figure 17. Overactive Bladder Diagnosis and Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 18. Global Overactive Bladder Diagnosis and Treatment Sales Market Share by Region (2017-2022)
Figure 19. Global Overactive Bladder Diagnosis and Treatment Sales Market Share by Region in 2021
Figure 20. Global Overactive Bladder Diagnosis and Treatment Revenue Market Share by Region (2017-2022)
Figure 21. Global Overactive Bladder Diagnosis and Treatment Revenue Market Share by Region in 2021
Figure 22. United States Overactive Bladder Diagnosis and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 23. Canada Overactive Bladder Diagnosis and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 24. Germany Overactive Bladder Diagnosis and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. France Overactive Bladder Diagnosis and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. U.K. Overactive Bladder Diagnosis and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. Italy Overactive Bladder Diagnosis and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. Russia Overactive Bladder Diagnosis and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. China Overactive Bladder Diagnosis and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. Japan Overactive Bladder Diagnosis and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. South Korea Overactive Bladder Diagnosis and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. India Overactive Bladder Diagnosis and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. Australia Overactive Bladder Diagnosis and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. China Taiwan Overactive Bladder Diagnosis and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Indonesia Overactive Bladder Diagnosis and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. Thailand Overactive Bladder Diagnosis and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Malaysia Overactive Bladder Diagnosis and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Mexico Overactive Bladder Diagnosis and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Brazil Overactive Bladder Diagnosis and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Argentina Overactive Bladder Diagnosis and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. Colombia Overactive Bladder Diagnosis and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. Turkey Overactive Bladder Diagnosis and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 43. Saudi Arabia Overactive Bladder Diagnosis and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 44. UAE Overactive Bladder Diagnosis and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 45. Sales Market Share of Overactive Bladder Diagnosis and Treatment by Type (2017-2022)
Figure 46. Manufacturing Cost Structure of Overactive Bladder Diagnosis and Treatment
Figure 47. Manufacturing Process Analysis of Overactive Bladder Diagnosis and Treatment
Figure 48. Overactive Bladder Diagnosis and Treatment Industrial Chain Analysis
Figure 49. Channels of Distribution
Figure 50. Distributors Profiles
Figure 51. Bottom-up and Top-down Approaches for This Report
Figure 52. Data Triangulation
Figure 53. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Astellas Pharma Inc Teva Pharmaceutical Industries Pfizer Inc Abbvie Inc Viatris Inc Hisamitsu Pharmaceutical Johnson & Johnson Services Endo Pharmaceuticals Lupin KYORIN Pharmaceutical Amneal Pharmaceuticals Sun Pharmaceutical Industries Glenmark Macleods Pharmaceuticals Medtronic Ajanta Pharma Granules India Urovant Sciences Apotex Inc.